Last reviewed · How we verify
Darvias (DARINAPARSIN)
Darvias works by inhibiting the enzyme glutathione S-transferase pi (GSTP1), which is involved in the cell's detoxification process.
Darvias (DARINAPARSIN) is a small molecule developed by Solasia Pharma K.K. It is used to treat refractory peripheral T-cell lymphoma, a type of blood cancer. The exact mechanism of action is not well understood, but it is believed to work by interfering with the cell's ability to produce proteins. Darvias is a patented medication, and its commercial status is owned by Solasia Pharma K.K. Key safety considerations include potential side effects such as neuropathy and myelosuppression.
At a glance
| Generic name | DARINAPARSIN |
|---|---|
| Sponsor | Solasia Pharma K.K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Think of it like a cell's recycling center. GSTP1 helps the cell get rid of bad stuff, but Darvias blocks this process, causing the cell to accumulate toxic waste and eventually die. This can be effective against cancer cells, but it also affects healthy cells, leading to potential side effects.
Approved indications
- Refractory peripheral T-cell lymphoma
Common side effects
Key clinical trials
- A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (PHASE2)
- A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) (PHASE1)
- A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea (PHASE1)
- A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma (PHASE2)
- A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b (PHASE2)
- Phase I Trial of ZIO-101 in Patients With Solid Tumors (PHASE1)
- Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas (PHASE1)
- A Phase I Trial of ZIO-101 in Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Darvias CI brief — competitive landscape report
- Darvias updates RSS · CI watch RSS
- Solasia Pharma K.K portfolio CI